Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates

Journal of Neurochemistry

Volumn 98, Issue 6, 2006, Pages 1866-1875

  Quik, Maryka ^a   Parameswaran, Neeraja ^a   McCallum, Sarah E ^a   Bordia, Tanuja ^a   Bao, Shanshan ^a   McCormack, Alison ^a   Kim, Amy ^a   Tyndale, Rachel F ^b   Langston, J William ^a   Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

MPTP; Nicotine; Nicotinic; Non human primates; Parkinson's disease; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; NICOTINE; NICOTINIC RECEPTOR; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL LOSS; CIGARETTE SMOKING; CONTROLLED STUDY; DATA ANALYSIS; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DRUG EFFECT; FEMALE; INCIDENCE; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; MONOAMINE OXIDASE; NERVE DEGENERATION; NEURONS; NEUROTOXINS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SAIMIRI; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; PRIMATES;

EID: 33748159130     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04078.x     Document Type: Article

References (54)

1. Allam M. F., Campbell M. J., Hofman A., Del Castillo A. S. and Fernandez-Crehuet Navajas R. (2004) Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 19, 614-621.
2. Behmand R. A. and Harik S. I. (1992) Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J. Neurochem. 58, 776-779.
3. Belluardo N., Mudo G., Blum M. and Fuxe K. (2000) Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav. Brain Res. 113, 21-34.
4. 3H]nicotine binding sites in human brain. J. Neurochem. 50, 1243-1247.
5. Berman S. B. and Hastings T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
6. 125I]-α-bungarotoxin binding in human postmortem brain. J. Comp. Neurol. 387, 385-398.
7. Carr L. A. and Rowell P. P. (1990) Attenuation of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology 29, 311-314.
8. Checkoway H. and Nelson L. M. (1999) Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10, 327-336.
9. Costa G., Abin-Carriquiry J. A. and Dajas F. (2001) Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336-342.
10. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J. Pharmacol. Exp Ther. 282, 445-451.
11. Fowler J. S., Volkow N. D., Wang G. J. et al. (1996a) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379, 733-736.
12. Fowler J. S., Volkow N. D., Wang G. J. et al. (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl Acad. Sci. USA 93, 14065-14069.
13. Gash D. M., Zhang Z., Ovadia A. et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255.
14. Gentry C. L. and Lukas R. J. (2002) Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord. 1, 359-385.
15. Hadjiconstantinou M., Hubble J. P., Wemlinger T. A. and Neff N. H. (1994) Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J. Pharmacol. Exp. Ther. 270, 639-644.
16. Harvey B. K., Hoffer B. J. and Wang Y. (2005) Stroke and TGF-β proteins: glial cell line-derived neurotrophic factor and bone morphogenetic protein. Pharmacol. Ther. 105, 113-125.
17. Hukkanen J., Jacob P. III and Benowitz N. L. (2005) Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79-115.
18. Janson A. M., Fuxe K., Agnati L. F., Kitayama I., Harfstrand A., Andersson K. and Goldstein M. (1988) Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 455, 332-345.
19. Janson A. M., Fuxe K. and Goldstein M. (1992) Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin. Invest. 70, 232-238.
20. Kemmerer E. S., Desmond T. J., Albin R. L., Kilbourn M. R. and Frey K. A. (2003) Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp. Neurol. 183, 81-86.
21. Lang A. E. and Obeso J. A. (2004) Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309-316.
22. Langston J. W. (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47, S153-S160.
23. Langston J. W., Quik M., Petzinger G., Jakowec M. and Di Monte D. A. (2000) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. 47, S79-S89.
24. Lloyd G. K. and Williams M. (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 292, 461-467.
25. Marks M. J., Burch J. B. and Collins A. C. (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther. 226, 817-825.
26. Masserano J. M., Gong L., Kulaga H., Baker I. and Wyatt R. J. (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharmacol. 50, 1309-1315.
27. Matta S. G., Balfour D. J., Benowitz N. L., Boyd T., Buccafusco J. J. et al. (2006) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (in press).
28. McCormack A. L., Di Monte D. A., Delfani K., Irwin I., DeLanney L. E., Langston W. J. and Janson A. M. (2004) Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471, 387-395.
29. McLaughlin B. A., Nelson D., Erecinska M. and Chesselet M. F. (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70, 2406-2415.
30. Morens D. M., Grandinetti A., Reed D., White L. R. and Ross G. W. (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45, 1041-1051.
31. Nutt J. G., Burchiel K. J., Comella C. L. et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73.
32. O'Neill M. J., Murray T. K., Lakics V., Visanji N. P. and Duty S. (2002) The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Target CNS Neurol. Disord. 1, 399-411.
33. Olanow C. W. (2004) The scientific basis for the current treatment of Parkinson's disease. Annu. Rev. Med. 55, 41-60.
34. Parain K., Marchand V., Dumery B. and Hirsch E. (2001) Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 890, 347-350.
35. Parain K., Hapdey C., Rousselet E., Marchand V., Dumery B. and Hirsch E. C. (2003) Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 984, 224-232.
36. Patel N. K., Bunnage M., Plaha P., Svendsen C. N., Heywood P. and Gill S. S. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57, 298-302.
37. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J. Pharmacol. Exp. Ther. 275, 1030-1034.
38. Perry D. C., Davila-Garcia M. I., Stockmeier C. A. and Kellar K. J. (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289, 1545-1552.
39. Quik M. (2004) Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27, 561-568.
40. Quik M. and Di Monte D. A. (2001) Nicotine administration reduces striatal MPP+ levels in mice. Brain Res. 917, 219-224.
41. Quik M., Polonskaya Y., Gillespie A., G. K. L. and Langston J. W. (2000) Differential alterations in nicotinic receptor α6 and β3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration. Neuroscience 100, 63-72.
42. 125I-α-conotoxin MII binding sites to nigrostriatal damage in monkey. J. Neurosci. 21, 5494-5500.
43. Quik M., Chen L., Parameswaran N., Xie X., Langston J. W. and McCallum S. E. (2006) Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in MPTP-lesioned primates. J. Neurosci. 26, 4681-4689.
44. Rosenberg P. A. (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8, 2887-2894.
45. Ryan R. E., Ross S. A., Drago J. and Loiacono R. E. (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 132, 1650-1656.
46. Samii A., Nutt J. G. and Ransom B. R. (2004) Parkinson's disease. Lancet 363, 1783-1793.
47. Schoedel K. A., Sellers E. M., Palmour R. and Tyndale R. F. (2003) Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol. Pharmacol. 63, 96-104.
48. Schwartz R. D. and Kellar K. J. (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220, 214-216.
49. Shahi G. S., Das N. P. and Moochhala S. M. (1991) 1-Methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment. Neurosci. Lett. 127, 247-250.
50. Togasaki D., Hsu A., Samant M., Farzan B., DeLanney L., Langston J., Di Monte D. and Quik M. (2005) The webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci. Methods 145, 159-166.
51. Vander Borght T., Kilbourn M., Desmond T., Kuhl D. and Frey K. (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294, 577-583.
52. Wilson J. M. and Kish S. J. (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16, 3507-3510.
53. Wonnacott S. (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci. 20, 92-98.
54. Wonnacott S., Drasdo A., Sanderson E. and Rowell P. (1990) Presynaptic nicotinic receptors and the modulation of transmitter release. Ciba Found. Symp. 152, 87-101.